# LOTIS-3 (NCT03684694)

> Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

No report yet. It can be ordered.

- Drugs tested: loncastuximab tesirine plus ibrutinib
- Indication: advanced diffuse large B-cell or mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03684694
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: ADC Therapeutics S.A.
- Conditions: Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma
- Interventions: Loncastuximab Tesirine; Ibrutinib
- Enrollment: 136
- Primary outcome: Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: Phase 1: Number of Participants With Serious TEAEs
- Primary outcome: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
- Primary outcome: Phase 1: Number of Participants With Dose Interruptions
- Primary outcome: Phase 1: Number of Participants With Dose Reductions
- Primary outcome: Phase 2: Complete Response Rate (CRR)

## Indexed commentary on LOTIS-3 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lotis-3-nct03684694
